Establishment Labs Finalizes Distribution Agreement with Puregraft LLC
Establishment Labs Holdings Inc. (NASDAQ: ESTA) has amended its distribution agreement with Puregraft LLC to extend their collaboration through the end of 2022. This agreement allows the company to continue offering advanced solutions for fat grafting as part of their MotivaHybrid® procedure, which utilizes the Motiva Implants® for natural breast augmentation. This partnership aligns with Establishment Labs' focus on women's health and expanding its innovative breast aesthetics product line.
- Amended distribution agreement with Puregraft extends collaboration through 2022.
- Continues to enhance offerings for fat grafting with MotivaHybrid® procedure.
- Original distribution agreement had terminated earlier this year, indicating prior setbacks.
SANTA BARBARA, Calif., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced it has finalized an amendment to its distribution agreement with Puregraft LLC for Puregraft’s line of products for autologous adipose tissue harvesting and redistribution. This amended agreement, which now will continue through the end of 2022, modifies the terms of the original distribution agreement that had terminated earlier this year.
“We are pleased to have reached this modified understanding with Puregraft that will enable us to continue offering the most advanced solution for fat grafting as part of our MotivaHybrid® procedure, giving women the option of a natural breast augmentation utilizing their own adipose tissue and our innovative Motiva Implants®,” said chief executive officer Juan José Chacón-Quirós.
About Establishment Labs
Establishment Labs Holdings Inc. (NASDAQ: ESTA) is a global medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, by designing, developing, manufacturing and marketing an innovative portfolio of silicone gel-filled breast implants, branded as Motiva Implants®, the centerpiece of the MotivaImagine® platform. Motiva Implants® are produced at our two manufacturing sites that are compliant with ISO13485:2016, FDA 21 CFR 820 under the MDSAP program, and are currently commercially available in more than 80 countries through exclusive distributors or the Company’s direct salesforce. In March 2018, Establishment Labs received approval for an investigational device exemption (IDE) from the FDA and initiated the Motiva Implant® clinical trial in the United States in April 2018. In addition to Motiva Implants®, Establishment Labs’ product and technologies portfolio includes the Divina® 3D Simulation System and other products and services. Please visit our website for additional information at www.establishmentlabs.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). You can find many (but not all) of these statements by looking for words such as “approximates,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “would,” “may” or other similar expressions in this press release, and includes statements related our ability to commercialize Motiva Implants and Puregraft. Any statements that refer to projections of our future financial or operating performance, anticipated trends in our business, our goals, strategies, focus and plans, and other characterizations of future events or circumstances, including statements expressing general optimism about future operating results, related to the Company’s performance are forward-looking statements. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995. We caution investors that any forward-looking statements presented in this report, or that we may make orally or in writing from time to time, are expressions of our beliefs and expectations based on currently available information at the time such statements are made. Such statements are based on assumptions, and the actual outcome will be affected by known and unknown risks, trends, uncertainties and factors that are beyond our control. Although we believe that our assumptions are reasonable, we cannot guarantee future performance, and some will inevitably prove to be incorrect. As a result, our actual future results may differ from our expectations, and those differences may be material. Factors that could cause or contribute to these differences include, among others, those risks and uncertainties discussed in the Company’s annual report on Form 10-K filed on March 16, 2020, quarterly reports on Form 10-Q, and other filings made by the Company with the Securities and Exchange Commission. The risks included in those documents are not exhaustive, and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for us to predict all such risk factors, nor can we assess the impact of all such risk factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We are not undertaking any obligation to update any forward-looking statements. Accordingly, investors should use caution in relying on past forward-looking statements, which are based on known results and trends at the time they are made, to anticipate future results or trends.
Investor/Media Contact: David K. Erickson Establishment Labs Holdings Inc. 949-447-6671
FAQ
What did Establishment Labs announce on September 25, 2020?
How does the amended agreement benefit Establishment Labs?
What is the significance of the Motiva Implants®?
What challenges did Establishment Labs face regarding the distribution agreement?
What is the stock symbol for Establishment Labs?
